Perspective Therapeutics (CATX) Change in Receivables (2010 - 2026)
Perspective Therapeutics' (CATX) quarterly Change in Receivables came in at $52000.0 in Q1 2026, up 236.84% year-on-year from $15437.5 in Q1 2025, and up 130.06% quarter-over-quarter from -$173000.0 in Q4 2025.
Perspective Therapeutics (CATX) Change in Receivables (2010 - 2026) Analysis & Trends
Perspective Therapeutics has disclosed Change in Receivables across 17 years of filings, most recently posting $52000.0 for Q1 2026.
- Change in Receivables for Q1 2026 came in at $52000.0, up 236.84% year-over-year; the trailing twelve-month figure through Mar 2026 was -$20000.0 (up 97.83% YoY), and the FY2025 annual result was -$110000.0, up 89.51% from the prior year.
- Change in Receivables came in at $52000.0 for Q1 2026 at Perspective Therapeutics, up from -$173000.0 in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $618000.0 in Q3 2023 to a low of -$813000.0 in Q2 2024.
- The 5-year median for Change in Receivables is -$46000.0 (2025), against an average of -$87705.9.
- Across the five-year window, Change in Receivables surged 256.46% in 2023 and sank 16700.0% in 2024, its largest moves.
- Perspective Therapeutics' Change in Receivables stood at -$245000.0 in 2022, then tumbled by 131.02% to -$566000.0 in 2023, then soared by 61.66% to -$217000.0 in 2024, then rose by 20.28% to -$173000.0 in 2025, then jumped by 130.06% to $52000.0 in 2026.
- The last three Change in Receivables figures came in at $52000.0 (Q1 2026), -$173000.0 (Q4 2025), and -$46000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn | 42.00 Mn |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn | -444.00 Mn |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn | -13.00 Mn |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn | 117.00 Mn |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn | 117.90 Mn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | - |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn | -124.60 Mn |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn | -141.00 Mn |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn | 123.50 Mn |
| 10 | Perspective Therapeutics | 308.74 Mn | 308.74 Mn | - | 52,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 52,000.00 |
| Mar 31, 2026 | 52,000.00 |
| Dec 31, 2025 | -173,000.00 |
| Dec 31, 2025 | -173,000.00 |
| Sep 30, 2025 | -46,000.00 |
| Sep 30, 2025 | -46,000.00 |
| Jun 30, 2025 | 147,000.00 |
| Jun 30, 2025 | 147,000.00 |
| Mar 31, 2025 | -38,000.00 |
| Mar 31, 2025 | -38,000.00 |
| Dec 31, 2024 | -217,000.00 |
| Dec 31, 2024 | -217,000.00 |
| Sep 30, 2024 | 147,000.00 |
| Sep 30, 2024 | 147,000.00 |
| Jun 30, 2024 | -813,000.00 |
| Jun 30, 2024 | -813,000.00 |
| Mar 31, 2024 | -166,000.00 |
| Mar 31, 2024 | -166,000.00 |
| Dec 31, 2023 | -566,000.00 |
| Dec 31, 2023 | -566,000.00 |